Liver resection is beneficial for patients with colorectal liver metastases and extrahepatic disease

• Published in: Annals of translational medicine Vol. 8; no. 4; p. 109
• Main Authors: Hasselgren, Kristina, Isaksson, Bengt, Ardnor, Bjarne, Lindell, Gert, Rizell, Magnus, Strömberg, Cecilia, Loftås, Per, Björnsson, Bergthor, Sandström, Per
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 2020
• Subjects: cancer; Cancer and Oncology; Cancer och onkologi; chemotherapy; Colorectal liver metastases; extrahepatic disease (EHD); liver resection; Medicin och hälsovetenskap; Oncology; Original; Research & Experimental Medicine; survival; liver resection; extrahepatic disease (EHD); Colorectal liver metastases
• ISSN: 2305-5839; 2305-5847; 2305-5839
• DOI: 10.21037/atm.2019.12.125

Liver metastases are the most common cause of death for patients with colorectal cancer and affect up to half of the patients. Liver resection is an established method that can potentially be curative. For patients with extrahepatic disease (EHD), the role of liver surgery is less established.
This is a retrospective study based on data from the national quality registry SweLiv. Data were obtained between 2009 and 2015. SweLiv is a validated registry and has been in use since 2009, with coverage above 95%. Patients with liver metastases and EHD were analyzed and cross-checked against the national death cause registry for survival analysis.
During the study period, 2,174 patients underwent surgery for colorectal liver metastases (CRLM), and 277 patients with EHD were treated with resection or ablation. The estimated median survival time for the entire cohort from liver resection/ablation was 40 months (95% CI, 32-47). The survival time for patients treated with liver resection was 45 months compared to 26 months for patients treated with ablation (95% CI 38-53, 18-33, P=0.001). A subgroup analysis of resected patients revealed that the group with pulmonary metastases had a significantly longer estimated median survival (50 months; 95% CI, 39-60) than the group with lymph node metastases (32 months; 95% CI, 7-58) or peritoneal carcinomatosis (28 months; 95% CI, 14-41) (P=0.022 and 0.012, respectively). Other negative prognostic factors were major liver resection and nonradical liver resection.
For patients with liver metastases and limited EHD, liver resection results in prolonged survival compared to what can be expected from chemotherapy alone.